Home › Funds › OXFORD ASSET MANAGEMENT LLP › ABUS
OXFORD ASSET MANAGEMENT LLP position in ABUS
ARBUTUS BIOPHARMA CORP · Health Care
OXFORD ASSET MANAGEMENT LLP reported holding 939,043 shares of ABUS (ARBUTUS BIOPHARMA CORP) in its Q3 2026 13F filing — a position valued at US$4.5M, representing 2.57% of its reported portfolio and ranking #2 among its reported holdings. OXFORD ASSET MANAGEMENT LLP has disclosed ABUS holdings in 3 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How OXFORD ASSET MANAGEMENT LLP's ABUS position evolved
OXFORD ASSET MANAGEMENT LLP first disclosed a stake in ABUS in Q2 2025 at 12,143 shares (US$38K). The position peaked in Q3 2026 at 939,043 shares, worth US$4.5M. Across 3 filings, OXFORD ASSET MANAGEMENT LLP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 939,043 shares valued at US$4.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 12.14K | $37.52K | New |
| Q4 2025 | 21.63K | $104.05K | New |
| Q3 2026 | 939.04K | $4.49M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABUS and 13F data
ABUS (ARBUTUS BIOPHARMA CORP) is a Health Care company. 36 other funds we track also report a position in ABUS — the largest reported positions include Whitefort Capital Management, LP (US$75.8M), Two Seas Capital LP (US$38.9M), BlackBarn Capital Partners LP (US$10.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABUS
- Whitefort Capital Management, LP 15.79M sh · $75.81M · Q2 2026
- Two Seas Capital LP 8.14M sh · $38.93M · Q3 2026
- BlackBarn Capital Partners LP 2.21M sh · $10.63M · Q3 2026
- Deltroit Asset Management (UK) LLP 1.20M sh · $5.74M · Q3 2026
- Rangeley Capital, LLC 500.00K sh · $2.40M · Q2 2026
More on OXFORD ASSET MANAGEMENT LLP
FAQ
How long has OXFORD ASSET MANAGEMENT LLP held ABUS?
OXFORD ASSET MANAGEMENT LLP has disclosed ABUS holdings in 3 of the last 6 reported quarters, going back to Q2 2025.
What is OXFORD ASSET MANAGEMENT LLP's current position in ABUS?
As of Q3 2026, OXFORD ASSET MANAGEMENT LLP holds 939.04K shares of ABUS (ARBUTUS BIOPHARMA CORP), valued at $4.49M, representing 2.57% of its reported portfolio and ranking #2.
Has OXFORD ASSET MANAGEMENT LLP been buying or selling ABUS?
In the latest 13F filing (Q3 2026), OXFORD ASSET MANAGEMENT LLP newly opened its position in ABUS. The position peaked in Q3 2026 at 939.04K shares.
Which other funds hold ABUS?
Other major institutional holders of ABUS include Whitefort Capital Management, LP, Two Seas Capital LP, BlackBarn Capital Partners LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.